Funding for this research was provided by:
Ministry of Health, Labour and Welfare (nannti-ippann-004, nannti-ippann-018)
Japan Agency for Medical Research and Development (JP17ek0109104, JP17ek0109121)
Japan Agency for Medical Research and Development (JP18ek0109360)
Received: 9 July 2020
Accepted: 2 October 2020
First Online: 12 October 2020
Ethics approval and consent to participate
: This study was conducted in accordance with the Declaration of Helsinki and the ethical guidelines for epidemiological research in Japan. This study was approved by the Ethics Committee of Okayama University Hospital and Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences (approval number, Ken1904-023). Informed consent and permission to publish their data were obtained from all participants.
: No individual person’s data were presented in any form in this study, and therefore, no consent to publish is required.
: KS received speaker’s fee from Astra Zeneca K.K. KA received speaker’s fee from Chugai Pharmaceutical Co. MH has received unrestricted research grants from AbbVie Japan GK; Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Eisai Co., Ltd.; Nippon Kayaku Co., Ltd.; Mitsubishi Tanabe Pharma Co.; and Teijin Pharma Ltd. MH has received speaker’s fee from Boehringer-Ingelheim; Kissei Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; and Chugai Pharmaceutical Co., Ltd. MH is a consultant for AbbVie; Boehringer-Ingelheim; Kissei Pharmaceutical Co., Ltd.; and Teijin Pharma. HM is a consultant for AbbVie, Boehringer-Ingelheim, and Teijin.